Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02945150 · ClinicalTrials.gov registry record · Phase 4
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT02945150: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02945150 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02945150, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
Interventions
- DRUG elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02945150
The ClinicalTrials.gov registry entry for NCT02945150 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) is the first listed.
NCT02945150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02945150 about?
NCT02945150 is a clinical study titled "Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant". Proof of concept, open-label single center study for the donation of HCV positive kidneys to HCV negative patients, with preemptive, interventional treatment to prevent HCV transmission upon transplantation.
What is the current status of trial NCT02945150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2017-02-01. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT02945150?
The interventions under investigation include: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) (DRUG).
Who is sponsoring clinical trial NCT02945150?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.